INTRODUCTION
In adults and mature animals, dopamine induces selective renal and mesenteric vasodilation without directly affecting blood flow to the brain. 1, 2 We have recently demonstrated that in normotensive preterm infants in the immediate postnatal period dopamine also causes selective renal vasodilation and does not directly affect cerebral blood flow. 3 However, we did not find evidence for a dopaminergic mesenteric vasodilatory response in that patient population.
Indomethacin is widely used for the pharmacological closure of the patent ductus arteriosus in the preterm infant. 4 In addition to enhancing ductal closure, however, the drug causes significant but usually transient decreases in renal, mesenteric and cerebral blood flow, 5 -8 glomerular filtration rate, 9 -11 and renal sodium and free water excretion. 9 -11 Due to its renal vascular and epithelial effects, 9 -11 indomethacin has the potential to blunt the dopamineinduced renal vasodilation and diuretic response in the preterm infant.
Therefore, in the present study we have investigated whether indomethacin pretreatment affects the regional dopaminergic hemodynamic response and whether it attenuates the diuretic response to dopamine. It is important to note that, since we started the dopamine infusion 2 to 8 hours after the first dose of indomethacin and since the majority of the indomethacin-induced renal and mesenteric vasoconstriction resolves after 2 hours of the drug administration, 5, 6 our study was not designed to examine the effect of dopamine on the regional vasoconstrictive responses to indomethacin.
MATERIALS AND METHODS Enrollment Criteria
Preterm neonates in the neonatal intensive care unit of the Pennsylvania Hospital, University of Pennsylvania, Philadelphia, PA were enrolled in this prospective, nonrandomized, and nonblinded
OBJECTIVE:
We have previously demonstrated that dopamine induces selective renal vasodilation without affecting cerebral and mesenteric blood flow in 32 weeks' gestation normotensive preterm infants during the first postnatal day. In the present study, we have examined whether pretreatment with indomethacin affects the regional hemodynamic response to dopamine in >1 -day -old normotensive preterm infants with similar gestational age.
STUDY DESIGN:
The pulsatility index ( PI ) was used to assess the dopamine -induced changes in renal, mesenteric, and cerebral blood flow using color Doppler ultrasonography in 20 indomethacin -treated normotensive preterm neonates with patent ductus arteriosus ( gestational age: 27.2 ± 1.5 weeks; postnatal age: 35.7 ± 8.2 hours ). Dopamine ( 5 g / kg per minute ) was started 4.9 ± 2.1 hours ( range: 2 to 8 hours ) after the first dose of indomethacin to combat oliguria and / or impaired peripheral perfusion. Blood flow velocity measurements were obtained immediately before and 10 minutes after the start of dopamine with each subject serving as his / her own control.
RESULTS:
Dopamine increased heart rate and urine output but did not affect blood pressure at the dose applied. Dopamine decreased the PI in the renal and superior mesenteric artery ( 2.6 ± 1.32 vs. 1.61 ± 0.7 and 2.36 ± 1.12 vs. 1.76 ± 0.64, respectively; p < 0.05 ) whereas the PI in the middle cerebral artery remained unchanged. These results are consistent with a dopamineinduced increase in renal and mesenteric blood flow without an effect on cerebral blood flow. study between September 1998 and December 1999 if they met the following criteria: gestational age between 23 and 32 weeks by early prenatal ultrasound and/or physical examination; presence of a patent ductus arteriosus diagnosed by cardiac ultrasonography 3, 5 and treated with indomethacin; development of decreased urine output ( <2 ml/kg per hour) and/or poor peripheral perfusion (capillary refilling time >3 seconds) within 2 to 8 hours after indomethacin administration; normotension defined as mean arterial blood pressure between the 10th and 90th percentile for gestational and postnatal age; 12 lack of a significant metabolic and/or respiratory acidosis (pH a !7.2) and/or hypoxemia (P a O 2 !35 mm Hg), and hemoglobin values in the normal range for gestational and postnatal age. Exclusion criteria included previous dopamine administration; administration of a volume bolus <12 hours before enrollment; congenital heart disease, and perinatal depression.
Study Protocol
Following enrollment, organ blood flow velocity profiles were determined between 2 and 8 hours after the first dose of 0.2 mg/kg of intravenous indomethacin (''indomethacin'' measurements). Dopamine was then started at 5 g/kg per minute, and the second measurement of organ blood flow velocity profiles was carried out 10 minutes after the initiation of the dopamine infusion (''indomethacin+dopamine'' measurements). Every patient served as his/her own control. Arterial blood gas parameters were determined before the ''indomethacin'' measurements and repeated after the study period. Hemoglobin concentration, serum creatinine, and BUN were measured upon enrollment. None of the 20 preterm infants received volume boluses within 12 hours before enrollment, and ventilator settings and fluid administration were kept constant during the study period.
In 19 of the 20 patients, urine output during the last 6 hours before dopamine treatment was compared to that during the first 6 hours of dopamine administration. In the remaining patient, urine output could not be calculated due to specimen losses.
Measurement of Systemic Blood Pressure and Organ Blood Flow Velocity Profiles
In addition to routine heart rate monitoring, systolic, diastolic and mean arterial blood pressures were continuously monitored from an umbilical arterial catheter connected to a pressure transducer and displayed on a monitor (Marquette Electronic Ink, Milwaukee, WI). None of the patients had dampened arterial waveforms. Indomethacin was administered over a 20-minute period, and both indomethacin and dopamine were infused into a peripheral or central vein by calibrated infusion pumps.
Organ blood flow velocity measurements in the right renal artery (dorsolateral approach), SMA (longitudinal abdominal approach), MCA (temporal approach), and descending aorta (at the level of the diaphragm) were carried out with an Acuson XP color and a duplex Doppler unit using a 5.0/7.5-MHz sector probe (Acuson, Mountain View, CA) as described earlier. 3 The measurements were done by one of the investigators (D.C.W.) with the angle of insonation being kept at a <58 angle to the blood flow of the artery studied. The examination time was 10 minutes. As in the previous study, 3 we used the pulsatility index (PI) to evaluate the alterations in organ blood flow in response to dopamine administration. The PI provides a relative measure of the changes in vascular resistance and was calculated by a built-in software analysis package using the following equation: PI=(Peak systolic flow velocityÀLowest diastolic flow velocity)/Mean flow velocity. The changes in this Doppler index are inversely and significantly related to changes in organ blood flow in the human preterm neonate. 3, 13 The study was approved by the Institutional Review Board of the Committee of Protection of Human Subjects of the Pennsylvania Hospital and informed parental consent was obtained before enrollment.
Statistical Analysis
Data collected are given as means±SD unless indicated otherwise. Paired and unpaired t test (two-tail), one-factor ANOVA (Fisher protected least square difference test), and simple regression analysis were used for data analysis where applicable. A p<0.05 was considered significant.
RESULTS
All 20 patients required mechanical ventilation, had received surfactant within 20 minutes following delivery, had a patent ductus arteriosus diagnosed by cardiac ultrasound and treated with indomethacin, and were started on dopamine at 4.9±2.1 hours (range 2 to 8 hours) after the first dose of indomethacin. Gestational age and birth weight were 27.2±1.5 weeks (range=25 to 32) and 926±293 g (range=427 to 1488), respectively. Postnatal age at the time of the first organ blood flow velocity measurements (''indomethacin'' measurements) was 35.7±8.2 hours (range=27 to 53 hours). Ductal closure occurred in all patients following completion of the three-dose indomethacin course by the fourth postnatal day. None of the subjects had culture proven sepsis, congenital heart disease, grade 4 IVH, or laboratory and/or clinical signs consistent with perinatal depression. Two patients had a stable grade 3 IVH at the time of enrollment and two other patients developed NEC later in their clinical course. Eight of the 20 patients remained ventilated and/or required oxygen at 28 days of life with 4 patients requiring ventilatory support and/or oxygen at 36 weeks postconceptional age. Eighteen of the 20 patients survived to hospital discharge.
Most patients had primarily left-to-right shunting at the level of the ductus arteriosus during systole and none of the subjects had reversal of diastolic blood flow in the aorta, suggesting that ductal shunting was unlikely to be very large. However, we cannot comment whether ductal shunting at this level significantly affected renal and mesenteric blood flow or had an impact on the regional hemodynamic effects of dopamine.
Hemoglobin concentration, serum creatinine, and BUN were within acceptable range upon enrollment at 14.5±1.5 g/100 ml, 0.66±0.32 mg/100 ml, and 17.3±7.0 mg/100 ml, respectively. Arterial pH, PCO 2 and PO 2 remained unchanged during the study at 7.33±0.06 vs. 7.34±0.06, 41.2±7.9 vs. 39.9±6.9, and 83.1±26.3 vs. 76.5±18.8 mm Hg, respectively (NS). Oxygen saturation also remained stable during the study.
Effect of Dopamine on Heart Rate, Systolic, Diastolic and Mean Blood Pressure and Urine Output Following Indomethacin Administration Heart rate increased by 3.8±6.9% from 148±16 to 154±17 beats per minute following dopamine administration ( p<0.05, Figure 1a) . Although this small change is statistically significant, it is unlikely that it had any effect on the organ blood flow velocity measurements. 13 Mean blood pressure did not change significantly in response to 5 g/kg per minute of dopamine (40.6±7.2 vs. 41.4±7.6 mm Hg, NS, Figure 1b) . Similarly, there were no changes in systolic and diastolic blood pressure values following dopamine administration (NS, data not shown). Urine output increased from 3.3±1.9 to 5.2±1.4 ml/kg per hour ( p<0.05) during the first 6 hours of dopamine administration compared to the last 6-hour period before dopamine treatment. However, because in 11 patients indomethacin was started between 2 and 5 hours before dopamine, we also calculated the changes in urine output in the remaining 9 patients in whom the entire 6 hours of predopamine urine collection occurred on indomethacin. The increase in urine output remained significant for this group of preterm infants (3.8±1.5 vs. 5.5±1.4 ml/kg per hour; p<0.05; Figure 2a ).
Effect of Dopamine on Regional Blood Flow Velocity Profiles Following Indomethacin Administration
Dopamine had no effect on descending aorta (1.67±0.92 vs. Finally, as in our previous study, 3 we also noted a significant direct association between the baseline renal artery PI and the dopamineinduced percent decrease in the renal artery PI (Figure 2b ).
DISCUSSION
The findings of the present study demonstrate that pretreatment with indomethacin does not affect the dopamine-induced selective renal vasodilation 3 in normotensive preterm infants when dopamine administration is started at least 2 hours after indomethacin treatment. In addition, we found no evidence for a dopamineinduced selective cerebral vasodilation. This observation is of clinical significance and is consistent with earlier findings indicating that dopamine is devoid of potentially harmful selective cerebral hemodynamic effects in the preterm infant. 3, 14, 15 Finally, the present findings have also demonstrated that dopamine induces a significant decrease in mesenteric vascular resistance in the >1-day-old normotensive preterm infant. Interestingly, in our previous study in preterm infants with similar gestational but less advanced postnatal age, 3 we did not find evidence for a dopamine-induced selective mesenteric vasodilation.
Indomethacin causes a rapid decrease in cerebral, renal, and mesenteric blood flow with a maximum effect between 10 and 30 minutes after its administration 5, 6, 8 However, the majority of the indomethacin-induced decrease in the blood flow in these organs resolves after 2 hours of the drug administration. Because dopamine was started 2 to 8 hours after the first dose of indomethacin, the present study examined the effect of indomethacin pretreatment on the dopamine-induced regional blood flow changes after the majority of the acute vasoconstriction caused by indomethacin had been resolved. In addition, because the hemodynamic changes were detected after 10 minutes of the start of the dopamine infusion, it is unlikely that spontaneous changes in regional hemodynamics independent of a direct dopaminergic effect are responsible for the findings.
The dopamine-induced decrease in the PI in the renal artery indicates that indomethacin pretreatment does not attenuate the selective dopaminergic vasodilation at least when dopamine is started 2 to 8 hours after the first dose of indomethacin. This finding confirms our previous observations 3 and indicates the presence of functionally mature renal vascular dopamine receptors in the preterm infant. Because blood pressure remained unchanged, the decrease in the renal vascular resistance must have been associated Å with an increase in the total renal blood flow in these patients. We also found a significant relationship between the baseline renal artery PI and the dopamine-induced percent decrease in the renal artery PI. This observation also confirms our previous findings 3 and suggests that the higher the renal vascular resistance before dopamine administration, the greater the relative renal vasodilation induced by the drug. These observations are of clinical importance, indicating that dopaminergic increases in renal blood flow occur even in the indomethacin-treated preterm infant. Finally, dopamine administration was also associated with an increase in urine output during the first 6 hours of the drug infusion in the entire patient population as well as in those patients who received indomethacin !6 hours before dopamine treatment. However, spontaneous changes in urine output may have contributed to this finding and one may not extrapolate the observed increase in urine output to the entire course of indomethacin treatment because our study was not designed to examine the proposed 16, 17 and disputed 18, 19 protective effects of dopamine on the indomethacin-induced decreases in urine output and urinary electrolyte excretion.
Contrary to our previous findings, 3 we did find evidence for a selective dopaminergic mesenteric vasodilatory response in the subjects of the present study. The reason for this discrepancy is unclear. However, in addition to receiving indomethacin, the subjects of this study differed from those in our previous trial 3 by their more advanced postnatal age (35.5±8.2 vs. 12.9±9.6 hours; p<0.05). Because significant decreases in the sympathomimetic activity and the production of other vasoactive hormones affecting the cardiovascular system occur during the first postnatal days, 20, 21 we speculate that the ensuing decrease in the underlying mesenteric vascular tone by the second postnatal day may have resulted in an unimpeded dopaminergic vasodilatory response in the SMA. Because, unlike in the mesenteric circulation, the dopaminergic vasodilation in the kidneys is present immediately after birth, 3 we continue to suggest that there are differences in the rate of maturation between the renal and mesenteric dopaminergic systems in man 3 with the maturation of the dopaminergic system in the mesenteric circulation lagging behind that of the kidney.
In the normotensive preterm infants of the present study, 5 g/kg per minute of dopamine exerted minimal to no effects on heart rate and blood pressure, respectively. Although dopamine may increase the blood pressure at lower doses in preterm infants, 2,3,22 -25 no statistically significant increases in the blood pressure occurred in the present patient population. It has been suggested that the observed interindividual and interstudy differences in the cardiovascular responses to dopamine are primarily due to differences in the level of maturity, cardiovascular adrenergic receptor expression, dopamine metabolism, and the underlying production of endogenous vasoactive factors. 2, 26 In summary, the findings of this study demonstrate an intact renal dopaminergic vasodilatory response in the indomethacintreated preterm infant, at least 2 hours after the first dose of indomethacin. Although this finding is of primary pharmacodynamic and physiologic importance, it also bears direct clinical relevance and supports the proposed use of low-dose dopamine in the indomethacin-treated preterm infant. 2 However, it remains to be determined whether dopamine treatment attenuates the indomethacin-induced decrease in urine output and urinary solute excretion in this patient population. 16 -19 The results of this study also confirm earlier observations that dopamine is devoid of potentially harmful selective cerebral hemodynamic effects in preterm infants. 3, 14, 15 Finally, if confirmed, the observed dopaminergic mesenteric vasodilatory response in the >24-hour-old preterm infant is of potential clinical significance.
